Biocon informs about disclosure

20 Apr 2024 Evaluate
Biocon has informed about a notification as follows: ‘Biocon Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA), for our vertically integrated, complex drug product Tacrolimus capsule 0.5mg, 1mg and 5mg strengths, in South Africa. This is the Company’s first approval in this Country. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.’ The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

380.25 2.45 (0.65%)
16-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.75
Dr. Reddys Lab 1269.30
Cipla 1355.80
Zydus Lifesciences 910.00
Lupin 2220.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×